TechnoDerma Medicines new small molecule - TDM-105795
- Thread starter nick123
- Start date
- Reaction score
- 1,336
You derail every thread with absolute sh*t posting. Go away.
Could you refer to what you mean by the exact formula, if you are referring to it's molecular structure then yes it is included.
Yes that's what I meant, perfect. I just quickly searched it by ctrl+f. Will look further for it and try to get a custom quote. And will look for the company which synthesized it for TD in the first place (in the hope it wasn't TD themselves).
N1-(3,5-Dichloro-4-(3-(4-fluorobenzyl)-4-hydroxyphenoxy)phenyl)-N2-oxalyl hydroxylamine
N1-(3,5-Dichloro-4-(3-(4-fluorobenzyl)-4-hydroxyphenoxy)phenyl)-N2-oxalyl hydroxylamine | C21H15Cl2FN2O5 | CID 129199016 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists...
pubchem.ncbi.nlm.nih.gov
MW of 465D is (workable but) quite high unfortunately.
There’s a new study for some analogues of TDM.
“Results: The TDM group showed early induction of anagen. 857, 782, and 276 differentially expressed genes were identified between 3 groups. As a critical DEG in group TDM, Pclaf was positively related to the motivation of Wnt/beta-catenin and Hedgehog signaling pathways, with a high expression of Ki67 and cyclinD1.
Conclusion: TDM10842 accelerates the anagen entrance and the potential mechanism might be the activation of Wnt/beta-catenin and Hedgehog pathways. Pclaf serves as a critical molecule involved in pathway activation, and cyclinD1 is an important effector protein downstream of the pathways.”
Even though this study references TDM10842, we can also assume this is the same for TDM-105975 as this is the analogue they actually went forward with.
TDM-105975 should be classified as a “thyroxine receptor agonist” and its mechanism of action is the activation of Wnt/beta-catenin and Hedgehog pathways.
Study link: https://www.dovepress.com/thyroid-h...-in-mice-peer-reviewed-fulltext-article-CCID#
Credit: @FollicleGuardian for finding this new study
“Results: The TDM group showed early induction of anagen. 857, 782, and 276 differentially expressed genes were identified between 3 groups. As a critical DEG in group TDM, Pclaf was positively related to the motivation of Wnt/beta-catenin and Hedgehog signaling pathways, with a high expression of Ki67 and cyclinD1.
Conclusion: TDM10842 accelerates the anagen entrance and the potential mechanism might be the activation of Wnt/beta-catenin and Hedgehog pathways. Pclaf serves as a critical molecule involved in pathway activation, and cyclinD1 is an important effector protein downstream of the pathways.”
Even though this study references TDM10842, we can also assume this is the same for TDM-105975 as this is the analogue they actually went forward with.
TDM-105975 should be classified as a “thyroxine receptor agonist” and its mechanism of action is the activation of Wnt/beta-catenin and Hedgehog pathways.
Study link: https://www.dovepress.com/thyroid-h...-in-mice-peer-reviewed-fulltext-article-CCID#
Credit: @FollicleGuardian for finding this new study
Last edited:
- Reaction score
- 72
There's currently a GB running for this. 225$ + shipping for a 8-12 month supply, DM me for a discord invite if interested. Over halfway to MOQ
"Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing in its Phase 1b (MAD) clinical trial of topical TDM-105795 solution in patients with Androgenetic Alopecia (Androgenetic Alopecia). This second clinical trial in the program is a 28-day multiple dose escalation study entitled, “A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group, Multi-Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia”. Study objectives are to evaluate the safety and pharmacokinetics of topical TDM-105795 following repeated doses. Two U.S. clinical sites are currently participating in this study.
Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We also expect the current study results to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase 2 Androgenetic Alopecia study. The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”
“We look to the TDM-105795 Androgenetic Alopecia program as the first clinical anchor among our pipeline products for treatment of various dermatologic diseases,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We are working tobring a second pipeline product (Atopic Dermatitis) into clinical testing soon in mid-year.”
Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We also expect the current study results to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase 2 Androgenetic Alopecia study. The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”
“We look to the TDM-105795 Androgenetic Alopecia program as the first clinical anchor among our pipeline products for treatment of various dermatologic diseases,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We are working tobring a second pipeline product (Atopic Dermatitis) into clinical testing soon in mid-year.”
- Reaction score
- 180
Can you link the discord pls?
Where does it say they observed robust regrowth in phase I? Can only see them mentioning regrowth in the mice studies.
- Reaction score
- 173
"The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”
Technoderma Medicines Doses TDM-105795 in Phase 1b (MAD) Androgenetic Alopecia Multi-Dose Escalation Clinical Trial | FinancialContent Business Page
Technoderma Medicines Doses TDM-105795 in Phase 1b (MAD) Androgenetic Alopecia Multi-Dose Escalation Clinical Trial
markets.financialcontent.com
They're doing phase I over again? So they didn't get the expected results the first time I presume
- Reaction score
- 173
Is that what phase 1b means? Just doing phase 1 over?